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Abstract
It has been documented that ischemia reperfusion injury (IRI) in the liver is
associated with complement pathway activation. Thus, blocking complement 3 (C3)
genes using a small hairpin RNA (shRNA) can potentially prevent liver IRI.
Gene silencing of C3 in vivo was achieved via the administration of shRNA
prior to IRI. Liver IRI was evaluated using histopathology, serum alanine
aminotransferase

(ALT),

and

aspartate

aminotransferase

(AST).

Neutrophil

accumulation was determined by myeloperoxidase assay. Oxidative stress was
assessed by malondialdehyde

and reactive oxygen species levels.

In comparison with control mice treated with scrambled shRNA, the serum
levels of ALT and AST were significantly reduced in mice treated with C3 shRNA.
Additionally, neutrophil accumulation and lipid peroxidase-mediated tissue injury
were decreased after shRNA treatment.

Tissue histopathology showed an overall

amelioration of injury in shRNA-treated mice. Therefore, the silencing of the C3 gene
proved to be a potential therapy for preventing hepatic IRI.

Keywords: IRI, C3, Complement, RNA interference
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Chapter 1: Introduction
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1.1 Ischemia-reperfusion injury
Ischemia-reperfusion injury (IRI) occurs when a tissue is temporarily
deprived of blood due to factors in the blood vessels, followed by the restoration of
the blood supply resulting in an intense inflammatory reaction. Reperfusion of
ischemic tissue after a period of ischemia can actually be more damaging than the
ischemia itself. IRI is a key event in clinical conditions such as stroke, myocardial
infarction, trauma, shock and solid organ transplantation [1-6].

Ischemic injury occurs when blood supply to organ tissues is blocked. Since
blood is responsible for the delivery of oxygen and nutrients to tissues, an insufficient
amount of blood will result in a lack of nutrients and hypoxia (when a region of the
body is deprived of adequate oxygen supply) or anoxia (a complete deprivation of
oxygen supply): conditions that will eventually lead to tissue damage. The metabolic
waste build-up produced from the lack of oxygen will cause further and more severe
damage in the ischemic tissue. The length of time a tissue can tolerate anoxia can
varies. However, all the ischemic tissue will eventually become necrotic. The heart
and the brain are organs that are susceptible to the most rapid damage if ischemia
should occur. Ischemic injury in these organs that last 3-4 minutes will result in
irreversible necrosis.

As previously mentioned, aerobic metabolism is interrupted during ischemia
causing an accumulation of metabolic waste. When reperfusion allows oxygen to be
available again, the aerobic metabolism resumes and generates reactive oxygen
species (ROS). These ROS will then cause oxidative cell damage including

oxidations on DNAs, proteins and lipids. Cell damage can stimulate the synthesis of
inflammatory cytokines and increase the expression of adhesion molecules, all of
which will cause neutrophils and macrophages to accumulate and attack the
reperfused tissue. Experimental animal models and observations obtained from
patients undergoing surgery have proven that oxidative stress and inflammatory
response will further induce tissue injury after reperfusion. [7-10],

1.2 Liver IRI

Although the liver receives a dual blood supply from the hepatic arteries and
the portal vein and has a glycogen storage system which supports the anaerobic
metabolism, ischemic and hypoxic injury of this organ is still quite common. This is
due to the fact that the liver is a highly aerobic organ, making it acutely sensitive to
hypoxic injury. Liver IRI occurs during hepatic surgical resection, liver
transplantation, trauma, and hemorrhagic shock, which can lead to local or systemic
organ dysfunction. During liver transplantation, IRI can cause up to 10% of early
organ failure and can lead to highly severe consequences such as acute or chronic
rejection [11-13]. Furthermore, marginal livers are highly susceptible to IRI, which
contributes to the shortage of donor organs available for transplantation. Therefore,
preventing patients from IRI is likely to increase the success of the transplantation.

Warm hepatic IRI is a major consequence of hepatectomy, liver
transplantation and hemorrhagic shock. The intense inflammation triggered by IRI
can lead to liver dysfunction or failure. There are two distinct phases of liver injury
after warm IRI [14]. The initial phase is mediated by activated Kupffer cells,
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releasing ROS which directly injures hepatocytes, while in the secondary phase
neutrophils enter the liver and augment the hepatocellular injury.

1.2.1 Types of Liver ischemia

There are two types of liver ischemia: cold ischemia and warm ischemia. Cold
ischemia occurs during the period of graft preservation at 1-4 °C prior to
transplantation. The major targets of cold ischemia injury are the nonparenchymal
cells, such as sinusoidal endothelial cells (SEC) and Kupffer cells, which are affected
within 30-60 min of reperfusion. In contrast, the hepatocytes remain morphologically
well preserved even after extended periods of cold preservation [15, 16]. The function
of the graft following transplantation correlates with the degree of SEC injury.
A cold preservation solution was developed in the mid-1980s at the
University of Wisconsin (UW) [17]. This solution contains a cocktail of substances
including lactobionate, raffinose, phosphate buffer, glutathione, colloids, and other
various ions which together decreases lethal reperfusion injury to SECs after longer
periods of cold storage. It also increases the safety of organ preservation for up to 24
hours. This remarkable solution has made a breakthrough in liver transplantation
worldwide [18].
Warm ischemia is used to describe the ischemia of cells and tissues under
normothermic conditions. It occurs during liver transplantation, various forms of
shock, trauma, and liver surgery. In the case of a liver transplantation, warm ischemia
occurs during implantation: from the time the organ is removed from ice until it is re-
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perfused with recipient blood. In the donor, warm ischemia may occur in the case of
non-heart-beating donor (NHBD) organ retrievals [19].
The injuries resulting from warm ischemia are different from those of cold
ischemia. The main feature of warm ischemia injury is an early (3-6 hr) and largescale apoptosis of hepatocytes after reperfusion. Cold preservation can protect organs
by suppressing metabolism, but it does not completely abolish metabolism. During
the cold preservation, cellular energy stores are slowly exhausted, intracellular pH
and calcium concentrations are increased, and lysosomal enzymes are activated. Since
the energy-dependent sodium/potassium pumps are also inactivated in this process,
sodium influx and cellular swelling will occur. During re-warming at the time of
implantation, cellular metabolic demand is increased. However, there is still a lack of
oxygen and nutrients, which will significantly worsen the hepatocellular structure and
its function. A relatively short period of warm ischemia is therefore more harmful to
cells than a longer period of cold ischemia [20]. The degree reperfusion injury is
correlated with the duration of ischemia: such that ischemia is tolerated only for a
period of approximately 1 hr in normal livers and 30 min in cirrhotic livers [21]. At
present, there is no efficient clinical treatment to prevent hepatic warm IRI in liver
transplantation.

1.2.2 Phases of warm IRI in liver

Dr. Jaeschke and his coworkers established that there are two distinct phases
of warm IRI of the liver [22-26]. The initial phase (2-3 hr after reperfusion) is
mediated by Kuppfer cell activation and the production of ROS, such as superoxide
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anion (O2 ) and hydrogen peroxide (H2O2) which directly injure hepatocytes.
Complement activation is also critical in the initial phase of IRI as depletion of
complement with cobra venom factor reduces Kupffer cell-induced oxidant stress [25,
27]. The severe injury that develops during the late phase (6-48 hr after reperfusion)
is mediated by recruited neutrophils that accumulate in the post-ischemic liver. The
activation of the Kupffer cells in the initial phase triggers a cascade of inflammatory
mediators which lead to the adhesion of neutrophils to the hepatic vascular
endothelium and subsequent transmigration into the hepatic parenchyma. The
activated neutrophils release ROS, elastase, cathepsin G, heparanase, collagenase and
hydrolytic enzymes which lead to an inflammatory disorder that causes direct damage
to hepatocytes [28-30],

1.2.3 Mechanisms of warm liver IRI

Warm liver IRI is a complex pathophysiology with a number of contributing
factors (Figl.l). Oxidative stress and an excessive inflammatory response are two key
mechanisms of injury during reperfusion [20, 31]. In the initial period of reperfusion,
reperfusion activates Kuppfer cells which can release ROS and pro inflammatory
cytokines such as tumor necrosis factor-alpha (TNF-a) and interleukin 1 alpha (ILla). Complement activation and CD4+ T cell activation cause a continuous activation
of Kuppfer cells [27, 32, 33]. Pro inflammatory cytokines, activated complement
factors, CXC chemokines and adhesion molecules are responsible for the
accumulation of neutrophils and its activation. Neutrophils induce inflammatory
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responses and also release ROS, which will damage hepatocytes in the later phases of
reperfusion injury [34],

Figure 1.1 The Mechanism of warm liver IRI

There are two phases of warm liver IRI: initial phase and late phase. In the initial
phase, Kupffer cells are activated and neutrophils are recruited by ROS and
proinflammatory cytokines. In the late phase of reperfusion, an excessive
inflammatory response caused by the accumulation of neutrophils leads to the injury
of hepatocytes.
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1.2.4 Cell types involve in warm liver IRI
Kupffer Cells

Kupffer cells are specialized macrophages which reside in the lining of the
hepatic sinusoids that form a part of the reticuloendothelial system (RES) of the liver.
In the initial stages of reperfusion, the activated Kupffer cells change their
morphology and protrude into the sinusoids, which causes blood flow within the
sinusoidal lumen to be reduced [35]. After 2-6 hr of reperfusion, activated Kupffer
cells release a large amount of pro inflammatory cytokines, reactive oxygen species,
chemokines and other mediators, all of which promote neutrophil accumulation and
oxidative stress. During the late phase of reperfusion, chemoattractants released from
Kupffer cells, cause activation and infiltration of neutrophils that lead to hepatocyte
injury.

Neutrophils

Neutrophils are the most abundant type of white blood cells in mammals and
form an essential part of the innate immune system. They are one of the first
inflammatory cells to migrate toward the site of inflammation. To migrate to the site
of infection or inflammation, neutrophils undergo a process called chemotaxis. This is
when cells direct their movements according to the level of certain chemicals in the
environment. Neutrophils have receptors on their surface that detect chemical
molecules such as interleukin-8 (IL-8), interferon gamma (IFN-y), complement 5a
(C5a) and Leukotriene B4 which direct them through their path of migration.
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Neutrophils are involved in both phases of hepatic IR injury. Chemoattractant
molecules produced from Kupffer cells cause hepatic neutrophil infiltration at the
initial phase of reperfusion. Accumulation and adhesion of neutrophils results from
the interaction of selectins and integrins expressed in the membrane of neutrophils
and intercellular adhesion molecules (ICAM) expressed on the endothelial cells,
respectively. Pro inflammatory cytokines TNF-a and IL-la stimulate ICAM-1
expression in hepatic endothelial cells during hepatic IRI [36]. During liver
transplantation, the increase in ICAM-1 expression leads to acute liver rejection [37].
Neutrophil accumulation causes sinusoidal endothelial cell injury and contributes to
hepatic microvascular dysfunction after liver IRI. Activated neutrophils amplify IRI
through the release of the same mediators as those of Kupffer cells, but the number of
mediators is much greater. The ROS and proinflammatory cytokines lead to
irreversible tissue damage in the liver. Depletion of neutrophils results in the
prevention of hepatocellular injury [38, 39].

CD4+ T-Cells

The role of CD4+ T-cells in tissue inflammation and organ injury resulting
from IRI has been well documented [40, 41]. CD4+ helper T-cells infiltrate into the
liver within an hour after reperfusion and provide another signal for neutrophil
infiltration. CD4+ cells can be subdivided into Thl and Th2 cells. Thl cells can
secrete IFN-y, tumor necrosis factor-beta (TNF-ß) and Granulocyte-macrophage
colony-stimulating factor (GM-CSF). Interferon-gamma (IFN-y) and TNF-ß are
potent activators of Kupffer cells and promote TNF-a and IL -la proinflammatory
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cytokine release by Kupffer cells. IFN-y and GM-CSF may also directly act on
neutrophils and enhance their ability to damage liver tissues [42], CD4+ T cells have
been shown to aggravate microvascular and hepatocellular injury by activating the
endothelium, and increasing platelet adherence and neutrophil migration [43].
Immunosuppressants such as FTY720 and Sirolimus have been shown to ameliorate
hepatic IRI by preventing T cell infiltration [44-46]. CD4+ T depleted mice exhibit
decreased neutrophil infiltration, liver enzyme release, and hepatocellular necrosis in
a later stage after hepatic IR [32]. Recent studies have found that CD4+ T cells
function in liver IRI without the requirement of de novo Antigen-specific activation
and are dependent on the CD40L-CD40 pathway [33]. The costimulation pathway of
CD40L-CD40 has been identified as a potential therapeutic target for preventing liver
IRI [47, 48],

1.2.5 ROS and oxidative stress in the liver

ROS are one o f the first elements formed in the initial phase of reperfusion
injury [49]. ROS are chemically-reactive molecules containing oxygen. ROS include
hydroxyl radicals, the superoxide anion, and hydrogen peroxide which all play
important roles in cell signaling and homeostasis [50], The major cellular source of
ROS is the mitochondrion. Under normal conditions, ROS are cleared from the cell
by the activation of superoxide dismutase, catalase, glutathione peroxidase and other
molecules. Under environmental stresses, ROS levels are dramatically increased,
resulting in significant damages to cell structures. This situation is known as
oxidative stress.
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Kupffer cells are the main source of ROS during the initial phase of IRI in the
liver. After liver IR, the peroxidation of lipids and the oxidant of protein frequently
occur through forming peroxynitrite [51, 52]. Peroxynitrite is recognized as an
important toxic intermediate in oxidative tissue injury. Proinflammatory cytokines,
activated complement factors 3a and 5a (C3a and C5a, respectively), and chemokines
are responsible for neutrophil recruitment and the subsequent neutrophil-induced
oxidative stress during the later reperfusion phase. Complement factors cause the
continuous stimulation of Kupffer cells and lead to prolonged oxidant stress [53].
Kupffer cell and neutrophil-induced oxidant stress is an important factor in vascular
and parenchymal cell injury during reperfiision. The ROS from the Kupffer cells and
neutrophils can directly kill hepatocytes. The mechanisms o f oxidant stress induced
cell killing includes the oxidation of pyridine nucleotides, the accumulation of
calcium in the mitochondria and the formation of superoxides by the mitochondria,
which ultimately lead to the formation of membrane permeable transition pores and
the breakdown of mitochondrial membrane potential. In addition to the direct
cytotoxic effects, ROS can promote reperfiision injury through the stimulation of
redox-sensitive transcription factors such as the nuclear factor-kappaB (NF-kB) and
the activator protein-1 (AP-1) in endothelial cells and hepatocytes [54], The
administration of antioxidants, particularly in the initial stages of reperfiision, could
significantly decreases the severity of IRI in transplanted livers [49].
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1.2.6 Cytokines in liver IRI

Pro inflammatory cytokines play an important role in both starting and
maintaining the inflammatory response in liver IRI. Cytokine levels also modulate the
severity of injury after reperfusion. In addition to reactive oxygen and proteases,
Kupffer cells are the major source of cytokines during reperfusion. TNF-a and IL-la
are generated during reperfusion [55, 56]. These cytokines have high
proinflammatory activity which inducing interleukin-6 (IL-6) and interleukin 8 (IL-8)
synthesis. IL-8 is a potent neutrophil chemotactic factor and activating factor, and
correlates with neutrophil infiltration in an IR model [57]. Adhesion molecules,
together with chemokines and complement factors, recruit neutrophils amplify
ischemic injury by releasing additional ROS, TNF-a, and diverse proteases [58]. Both
TNF-a and IL -la can upregulate macrophage 1 antigen (Mac-1) on neutrophils and
recruit these cells into the liver vasculature. In addition, they are also potent inducers
of hepatic CXC chemokine synthesis [59].

TNF-a

TNF-a is a cytokine produced by numerous cell types in response to
inflammatory and immunomodulatory stimuli. The primary role of TNF-a is to
regulate immune cells. TNF-a is able to induce apoptotic cell death and inflammation,
inhibit tumorigenesis, and promote cell regeneration. Liver production of TNF-a does
not occur during hepatic ischemia, but serum and hepatic levels of TNF-a are rapidly
elevated after reperfusion. The secreted TNF-a has local hepatic and remote systemic
organ effects, notably on the lung. In turn, TNF-a induces Kupffer cells to proliferate

15

more TNF-a [60]. TNF-a enhances oxidative stress-induced injuries and induces
apoptosis in hepatocytes. As a central mediator in the liver IRI, it is clear that TNF-a
is responsible for increasing adhesion molecule P-selectin, intracellular adhesion
molecule 1 (ICAM-1), and chemokine expression, which further promote neutrophil
migration into the hepatic microvasculature [61, 62]. Blockade o f TNF-a prevents the
expression of adhesion molecules as well as the expression o f CXC chemokines
which can attenuate neutrophil accumulation and subsequent liver injury [63, 64].

IL-la

IL -la is produced by various types o f cells, including macrophages, dendritic
cells (DC), T-cells, and B-cells. In liver IRI, IL-la is also released by activated
Kupffer cells and promotes ROS formation. IL -la is released in response to TNF-a
and also upregulates free radical production by neutrophils [65]. Unlike TNF-a,
which is expressed rapidly after reperfusion, IL -la expression is delayed and does not
affect the expression of TNF-a. IL -la plays an important role in the induction of
CXC chemokines, macrophage inflammatory protein 2 (MIP-2) expressions, and
activation of NF-xp. These effects augment neutrophil accumulation in the liver but
do not significantly alter the extent of hepatocellular injury. IL -la plays an accessory
role in inflammatory responses [66],

Interleukin 12 (IL-12)

IL-12 is an interleukin that is naturally produced by dendritic cells and
macrophages in response to antigenic stimulation. It plays an important role in T cell
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differentiation and stimulates the growth and function of T cells. It stimulates the
production of interferon-gamma (IFN-y) and TNF-a from T cells, and reduces the IL4 mediated suppression of IFN-y [67]. IL-12 plays a central role in the induction of
hepatic ischemia-reperfusion injury by regulating the production of TNF-a and IFN-y
[68, 69], Lentsch et al. showed that the hepatic expression of IL-12 is upregulated
during the period of ischemia [22, 69]. Mice treated with a neutralizing antibody to
IL-12 as well as IL-12 p40 deficient mice displayed a production of TNF-a and IFN-y
that was greatly reduced. Furthermore, hepatic neutrophil accumulation and
hepatocellular injury were also greatly reduced. Thus, it is concluded that IL-12 plays
an important role in the liver inflammatory response to ischemia and reperfusion.

1.2.7 Adhesion molecules in liver IRI

During the initial phase of liver reperfusion injury, Kupffer cells are activated
and release pro inflammatory cytokines (TNF-a and IL-la) to recruit neutrophils. For
neutrophil accumulation at the site of inflammation, three classes of cellular adhesion
molecules (CAM) on the surface of neutrophils and SECs are activated. They are
se lectins, integrins and members of the immunoglobulin superfamily.
Selectins are lectin-domain glycoproteins expressed on endothelial cells,
platelets, and neutrophils. Selectins mediate the initial capture of leukocytes, and
support the rolling and transit adhesion on to the vascular endothelium, respectively.
P-selectin plays a major role in the earliest phase of rolling and adherence of
neutrophils in the hepatic microvasclulature after IRI. There are two peaks of P-
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selectin expression after liver IRI. One occurs at 20 minutes and another at 5 hours
after reperfusion [70, 71]. The increased neutrophil-endothelium interaction
mediated by se lectins enhances the other two CAM’s engagement. P-se lectin
expression also plays an important role for the adhesion of platelets to the hepatic
endothelium [72], The adherent platelets are known to augment neutrophil adhesion
at the sites of inflammation [73]. P-selectin deficiency significantly reduce the
severity o f hepatic IRI [72, 74].
The (32 integrins on neutrophils (i.e., Mac-1) bind to immunoglobulin-like
adhesion molecules on the endothelial cells, leading to firm adhesion of neutrophils
on the endothelial surface. This may facilitate an increase in neutrophil extravasation
and migration to the inflammatory site. Intercellular adhesion molecules 1, 2 and 3
(ICAM-1, 2 and 3), vascular cell adhesion molecule (VCAM)-l, and platelet
endothelial cell adhesion molecule (PECAM)-l are members of the immunoglobulin
like family. There is a low expression of ICAM-1 on endothelium and Kupffer cells
in normal liver. Pro inflammatory cytokines can significantly stimulate ICAM-1
expression on endothelial cells, causing ICAM-1 -02 integrin interaction to promote
firm adhesion of neutrophils to SECs. Blocking ICAM-1 with a specific antibody can
efficiently prevent hepatic IRI [75, 76].
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1.2.8 Complement System

The complement system consists of about 30 soluble and membrane-bound
proteins and has long been recognized as an important mediator of innate immune
defense and inflammation [77]. Activation of the complement system is a critical
event in IR of both clinical and experimental studies [27, 78, 79]. There are three
biochemical pathways that activate the complement system, including the classical
pathway, the alternative pathway, and the mannose-binding lectin (MBL) pathway
[80-82] (Figure 1.2). These pathways depends are initiated by different molecules for
their initiation. The classical pathway is typically initiated when complement lq
(Clq) binds to the IgM or IgG antigen/antibody complex or when C lq binds directly
to the surface of the pathogen [83]. The alternative pathway is triggered by
spontaneous C3 hydrolysis to form C3a and C3b. C3b then binds to the pathogenic
membrane surface. The MBL pathway is activated by MBL binding to mannose
residues on the pathogen surface, which activates the MBL-associated proteases 1 and
2 (MASP1 and MASP2). MASP1 and MASP2 can split C4 into C4a and C4b and C2
into C2a and C2b. C4b and C2a then bind together to form C3-convertase, which
leads to the subsequent activation of C3 [84, 85]. A common feature of all three
pathways is that complement 3 (C3) convertase cleaves and activates the C3 protein,
creating C3a and C3b and causing a cascade of further cleavage and activation. C3b
joins with C3 convertase (C4b2a) to form C5 convertase which can be cleaved to
produce C5a and C5b. C5b induces the activation of the terminal complement and the

19

formation o f the membrane attack complex (MAC) which is the end product of the
complement activation pathway [86].
Hepatocytes are mainly responsible for the biosynthesis of 90% of plasma
complement components and their soluble regulators. Proinflammatory cytokines
such as IL-la, IL-6, TNF-a, and IFN-y can induce a significant increase in
complement components [87-89]. Complement cascade can be rapidly activated in
the early stage of IRI. Complement activation leads to the release of the small
complement fragments C3a and C5a, also known as as anaphylatoxins because they
can cause mast cell degranulation with the release of histamine and other mediators
that increase vascular permeability [90]. C3a and C5a upregulate the Mac-1 receptor
on neutrophils, cause neutrophil migration, and induce neutrophil adhesion within
sinusoids to produce a local inflammatory response [91, 92], They can also stimulate
oxidative metabolism to produce the ROS in Kupffer cells and neutrophils. MAC can
directly cause cell injury and stimulate arachidonate metabolism resulting in the
release of prostaglandin E2 from macrophages, leukotriene B4 from neutrophils, and
interleukin-1 and ROS from human monocytes [93, 94]. Since C3 plays a central role
in the complement system, blocking activation of the complement pathway has been
shown to be effective in reducing the pathology of various organ-specific IRI [27, 9598]. Therefore, suppression of C3 is a favorable strategy in turning off complement
activation to prevent IRI [99].
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Figure 1.2 Complement activation Pathway

There are three pathways for complement activation: the classical pathway, the
alternative pathway, and the lectin pathway. Each of these pathways is triggered by
different molecules on the pathogen surface. All three pathways result in C3
activation and merge at the level of C3 convertase, resulting in the formation of the
same effector molecules such asC5a and C5b-9 (membrane attack complex, MAC).
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1.3 RNA interference

RNA interference (RNAi) is an RNA-dependent process that permits
sequence-specific posttranscriptional gene silencing induced by double-stranded
RNA (dsRNA). Fire and Mello first announced their discovery of RNAi after
injecting dsRNA into the worm Caenorhabditis elegans resulting in the silencing of
the gene that had a complementary sequence to that of the introduced dsRNA [100].
In brief, the mechanism of RNAi requires that dsRNA be cleaved into small
interfering RNA (siRNA) by the RNase III enzyme Dicer. Next, the sense strand of
siRNA is removed and the antisense strand, which is complementary to the target
gene, is left behind to guide a protein complex called RNA induced silencing
complex (RISC) as it identifies and silences the target mRNA (Figure 1.3). Since its
discovery, RNAi offers enormous potential for using as a tool not only in biological
research but also therapeutics by silencing genes of interest.
Chemically synthesized siRNA and short hairpin RNA (shRNA) cloned into
vectors are both used to perform RNAi [101]. ShRNA contains a sense and antisense
strand and a loop sequence between two strands. Due to the complementarity of the
sense and antisense fragments in their sequences, such RNA molecules tend to form
hairpin-shaped dsRNA by flipping back on the loop sequence. The U6 or HI
promoter is used to ensure that the shRNA is constitutively expressed. Transcription
of shRNA is initiated by polymerase III (pol III) promoter in the nucleus and then
transported into the cytoplasm where the hairpin loop is cleaved by DICER resulting
in a 21 base pair double stranded siRNA which then triggers RNAi [102-104].
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Since it was first introduced by Fire and Mello, RNAi has shown promising
results in both research and clinical therapy in the past decade. Elbashir et al. first
used RNAi in mammalian cells [105] and Song et al. first reported that siRNA can
be used therapeutically in whole animals [106], In 2010, Davis et al. first
demonstrated that siRNA administered systemically to humans can produce specific
gene inhibition [107]. These studies highlight the enormous potential of using RNAi
as a powerful therapeutic tool.

Figure 1.3 RNAi mechanism

DsRNA is cleaved into small interfering RNA (siRNA) by the RNase III enzyme
Dicer. Next, the sense strand of siRNA is removed and the antisense strand, which
complementary to the target gene, is left behind to guide a protein complex called
RNA induced silencing complex (RISC) to identify and cleave the endogenous
mRNA.
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1.4 Rationale and significance
In our previous study, we successfully knocked down C3 gene through gene
silencing, which is effective in the prevention of IR injuries in cardiac IRI [108] and
renal IRI models [109-112]. However, gene silencing ofC3 to prevent liver IR injury
has not yet been tested. Currently, there is no effective way to prevent warm liver IRI
so the discovery o f a therapeutic strategy would be highly significant clinically.
Complement activation has been shown to be an early event in hepatic IRI. C3 is a
central molecule involved in the three pathways for complement activation. In this
study, I evaluated the therapeutic potential o f C3 shRNA knockdown in the
ameliorating liver IRI.

1.5 Hypothesis
Complement activation plays an important role in liver IRI. C3 is the central
and critical plasma protein of the three pathways of complement activation. Thus,
silencing the gene C3 with shRNA can alleviate liver IR in mice.

1.6 Specific aims
A. To validate C3 gene expression and silencing in vitro and in vivo.
B. To establish partial hepatic IR model.
C. To prevent hepatic IRI by silencing the C3 gene.
D. To find protective mechanisms of C3 shRNA in alleviation of Liver IR .

Chapter 2 Materials and Methods

2.1 C3 shRNA preparation

2.1.1 C3 shRNA design

Three sequences in C3 mRNA were selected for RNAi targeting. The
oligonucleotides contained target-specific sequences for C3, including C3-1 [5’GATCCCGTCTTTAGGAA GTCTTGCA CA GT7CAAGAGACTGTGCAA GA CTTCCT
AAAGA TTTTTTCCAAA-3’(sense) and 5’-AGCTTTTGGAAAAAA
TCTTTA GGAAGTCTTGCA CA GTCTCTT GAACTGTGCAAGA CTTCCTAAA GA
CGG-3’ (antisense)];C3-2 [5’- GATCCCGTTGTTCATAACCAGGTAGG
TT CAAG AG AC CTA CCTGGTTA TGAA CAA t t t TTT CCAAA-3 ’(sense) and 5’AGCTTTT GGAAAAAA TTG TTCA TAACCA GGTA GGTCTCTT GAA
CCTACCTGGTTATGAACAACGG-3\antisense)]; C3-3 [5’-GATCCCG
TTCAA CTCTTCTA TGGTCCA CTTCAAGAGAG TGGA CCA TA GAA GA GTTGAATT
TTTTCCAAA-3’ (sense) and 5’-AGCTTTTGGAAAAAA
TTCAA CTCTTCTA TGGTCCA CTCTCTTGAAG TGGA CCA TA GAAGAGTTGAA
CGG-3’ (antisense)]; the sequence for scrambled shRNA [5’-GATCCC
ACTA CCG TA G TCA TCGGAGTA TTG AT ATCCG TA CTCCGA TGA CTA CGGTA G TV
TTTTT GGAAA-3 ’ (sense) and 5 ’- AGCTTTTGGA AAAAA4 CTA CCG TAGTCA TC
GGAGTACGGATATCAATACTCCGATGACTACGGTAGTGG-T (antisense)] were
designed and synthesized by Invitrogen (Carlsbad, CA). The synthesized hairpin
siRNA oligonucleotides were annealed by mixing lpg of each sense and antisense
oligonucleotides with the DNA annealing solution and incubating at 90°C for 3 min
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then cooling at 37°C for 1 hr. The annealed shRNA was then ready for ligation with
plasmid vector.

2.1.2 Preparing the vector for ligation

The pRNAT U6.1/Neo siRNA expression vector (genescript, Piscataway, NJ)
was digested with BamHI and Hindlll restriction enzymes (NEB, Ipswich, MA) for
ligation. In brief, 10 pg of pRNATU6.1 vector was mixed with 10U of BamHI,
Hindlll and cut Buffer B (Roche, Laval, QC) and then incubated at 37 °C for lhr The
digested vector was extracted using a QIAquick gel extraction kit (Qiagen Canada,
Toronto, ON). The digested vector was then loaded into a 0.8% agarose gel and
allowed to run for lhr at 80V. The linearized DNA fragment was excised from the gel
with a clean, sharp scalpel. The gel slice was weighed, and added according to 3
volumes of buffer QG to 1 volume of gel (100mg~100pl). The mixture was then
incubated at 50 °C for 10 min. One gel volume of isopropanol (Sigma-Aldrich
Canada, Oakville, ON) was added and mixed. The mixture was placed into the
QIAquick spin column and centrifuged. Buffer PE was used to wash the column and
then Buffer EB was used for eluting the digested vector. The concentration of the
digested vector was measured by a spectrophotometer (Biorad, Mississauga, Ontario).

2.1.3 C3 shRNA expression vector ligation
A C3-shRNA expression vector that expresses hairpin siRNA under the
control of the mouse U6 promoter and cGFP gene was constructed by ligating the
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annealed DNA oligonucleotides into a pRNATU6.1 vector. (Figure 2.1) In brief, the
annealed shRNA was inserted and the digested pRNATU6.1 vector was mixed at a
molar ratio of 3:1. T4 DNA ligase (NEB) and ligation buffer were added to the
mixture and incubates at 16 for 1hr The ligated shRNA vector is now ready for the
transformation into competent DH5a cells (Invitrogen, Carlsbad, CA).

Figure 2.1 C3-shRNA vector (pRNAT-U6.1/Neo)

This figure demonstrates the C3 shRNA expression vector. The annealed C3 hairpin
siRNA oligonucleotides were inserted into the vector under the control of the mouse
U6 promoter. Before ligation, the vector was digested with BamHI and Hindlll
restriction enzymes. ShRNA transfection efficiency in vitro and delivery in vivo can
be tracked by the GFP marker controlled by CMV. It also contains the antibiotic
resistant genes for ampicillin and neomycin. Ampicillin allows for the selection of
C3 shRNA vector clones after transformation on an ampicillin containing plate.
Neomycin can be used to establish a stable transfection cell line in vitro.
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2.1.4 C3 shRNA vector transformation and mini preparation

DH5a competent cells (50 pi) were thawed and mixed with ligated shRNA
vector (lOng). The mixture was then put on ice for 10 min and put in a 42°C water
bath for 30 seconds afterwards. After the heat shock, the mixture was put back on ice
for 3 min. Two hundred microliters of LB medium (Sigma) was added to the mixture
and then incubated in a shaker at 37°C for lhr. The 200pl transformation mixture was
then spread on a pre-warmed ampicillin selective agar plate. The plate was incubated
overnight at 37°C.
A single fresh clone was picked from the overnight culture plate and added
into 5ml of LB medium. The E.coli cultures were then incubated in a shaker at 37°C
overnight. The plasmid DNA was purified using a QIAprep spin miniprep kit
(Qiagen). The overnight cultures of E.coli were harvested by centrifugation. Buffer
PI, P2, and P3 from the miniprep kit were added to the pellet and centrifuged again
\
for the collection o f the supernatant. The supernatant was transferred to a spin column
centrifuge and washed by Buffer PE. The purified C3 plasmid shRNA vector was
then eluted by Buffer EB and sent for a sequence test.

2.1.5 Large Scale plasmid preparation

The E. coli stock, which has the correct sequence targeting of the C3 gene,
was added to 500ml of LB medium and cultured at 37°C in a shaker overnight. The
bacteria were collected by centrifugation and solutions I, II, and III were added. The
supernatant from the centrifugation was filtered with a Kimwipes and isopropanol
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was added and centrifuged to collect the pellets. The pellets were then dissolved in
4ml TE buffer, and 4.21g CsCl (Sigma) and 200pl ethidium bromide (Sigma) were
added. The mixture was centrifuged at 55,000 rpm at 20°C overnight. The red
plasmid DNA band was pulled out using a syringe with an 18-gauge needle. Ethidium
bromide was then extracted using water-saturated isobutanol (Sigma). The plasmid
DNA was precipitated on ice by adding ethanol and then centrifuged. The pellets
were mixed with Rnase A (Fermentas, Burlington, ON) and purified using the
phenol-chloroform (Bioshop, Burlington, ON) method. The concentration of the C3
shRNA vector was measured by a spectrophotometer and was then ready for in vitro
and in vivo use.

2,2 Cell culture and C3 gene silencing in vitro

Mouse melanoma cell line B16-F10 cell (ATCC, Manassas, VA) were
cultures with Dulbecco's Modified Eagle's Medium. To validate gene silencing, B16F10 cells were co-transfected with C3 cDNA (Invitrogen, Carlsbad, CA), C3 shRNA,
or scrambled (nonsense) shRNA using lipofectamine 2000 (Invitrogen). The C3
cDNA alone and non-transfected B16 cells were served as controls. The B16 cells
were then plated into a 12 well plate (2xl05 of cells per well) and allowed to grow
overnight to reach 70% confluence. The cells were then transfected with 0.5 pg of C3
shRNA, 2pg of C3 shRNA, or scrambled shRNA in 500pl opti-MEM (Invitrogen) for
4 hr. 500pl of 20% FBS complete medium was added and cells were incubated for 24
hr. Subsequently, 1ml of complete medium was added and cells were incubated for
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24 hr. RNA was extracted from the transfected cells using Trizol (Invitrogen) and
prepared for subsequent analysis.

2.3 Flow cytometry

The B16-F10 cells were transfected with C3 shRNA using lipofectamine 2000.
At the different time point after transfection (4, 12, 24, and 48 hr after transfection),
the cells were harvested to check the GFP expression using flow cytometry. After the
B16-F10 cells were transfected with C3 shRNA vector in a 12 well plate, the cells
were washed by PBS at different time points. Then 0.05%Trypsin-EDTA was added
to the cells and incubated at 37°C for 3 minutes. Complete culture medium was
added to neutralize the trypsin and then the cells were collected and centrifuged. The
supernatant was discarded and the pellets of the cells were washed by a running
buffer containing 2% FBS in PBS. After centrifugation, the pellets were resuspended
in 300plof running buffer in preparation for analysis on a FACS caliber flow
cytometer (Becton Dickinson, San Jose, CA)

2.4 Mice
Male BALB/c mice, 6-8 week old, were purchased from Charles River
(Wilmington, MA). The mice were maintained under strict pathogen-free conditions
at the Animal Care and Veterinary Service of the University of Western Ontario. All
experiments were performed in accordance with the Guide for the Care and Use on
Animals Committee Guidelines.
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2.5 shRNA administration
In vivo gene silencing was performed based on a previously reported
“hydrodynamic” injection method. Forty-eight hours prior to the IRI experiment,
5mg/kg C3 shRNA and scrambled shRNA were diluted in 2ml of Ringer’s solution
and intravenously injected into the mice through the tail vein for 7-1 Os [113-115].

2.6 Liver IRI model

Experimental liver IRI model was performed as previously described [116].
BALB/c mice were anesthetized with ketamine (100mg/kg) and xylazine (20mg/kg)
by intraperitoneal injection. Mice were placed on a heated pad to maintain warm body
temperatures during the surgery. A midline laparotomy incision was performed to
expose the liver. The left lateral and median lobes of the liver were rendered ischemia
by completely clamping the hepatic artery and the portal vein using microaneurysm
clamps. This experimental model resulted in 70% segmental hepatic ischemia. After
clamp placement, the intestines where placed back into the abdominal cavity and 500
pi of 10U/ml heparinized saline was administered directly into the peritoneal cavity.
The incision area was covered with moistened gauze and the body temperatures of the
mice were maintained at 37°C. After 60 min of ischemia the clamp was removed and
the abdomen was closed. Blood and liver tissues were collected for experimentation
6hr and 24hr after reperfusion as described below.
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2.7 Assessment of liver function

When certain types of cells are damaged, they may leak enzymes into the
blood, where they can be measured as indicators of cell damage. Alanine
aminotransferase (ALT) is produced mainly in the liver and small amounts of this
enzyme are also found in the heart, muscle and kidney. It is significantly elevated in
hepatitis patients and other forms of acute liver damage. Aspartate aminotransferase
(AST), has a similar role, but is not as specific to the liver. It is also found in other
tissues, like the heart, muscles, kidneys, brain and lungs. When liver damage occurs
and is associated with hepatic necrosis, blood levels of ALT and AST are elevated
even before the clinical signs and symptoms of the disease appear. Therefore, ALT
and AST levels can be used for the assessment of liver function.
Blood samples were obtained from the inferior vena cava 6 hr and 24 hr after
reperfusion. The levels o f ALT and AST in the serum were measured by the Core
Laboratory at the London Health Science Centre.

2.8 Histopathology and Immunohistochemistry Examination

2.8.1 Frozen section

The C3 shRNA vector was administered to animals at different concentrations,
from l-7mg/kg. Forty-eight hours after the administration, the liver tissues were
collected and fixed in 4% paraformaldehyde (Sigma) solution for 4-8 hr. Tissues were
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then dissected and mounted in a Tissue-Tek optimum cutting temperature embedding
compound (Cedarlane, Burlington, ON), snap-frozen in liquid nitrogen, and stored in
-80°C. Five micrometer thick tissue sections were cut using a cryostat. GFP
expression was visualized using microscopy.

2.8.2 Liver histology

Six and twenty-four hours after reperfusion, liver tissues were collected and
tissue slices were fixed in 10% formalin for 3 days at room temperature. Tissues were
formalin-fixed embedded in paraffin, and 5pm thick sections were stained with
hematoxylin and eosin (H&E). These sections were examined in a blinded fashion by
a pathologist. The histological criteria for the assessment of liver damage after IRI
followed a standardized scale [117], in which the following parameters were
quantified: congestion, or vacuolization (0 None, 1 Minimal, 2 Mild, 3 Moderate, 4
Severe), and necrosis (0 None, 1 Single-cell of focal necrosis, 2 area of necrosis
<30%, 3 area of necrosis 30-60%, 4 area of necrosis >60%).

2.8.3 Immunohistochemistry

For the immunohistochemical staining of TNF-a and IL-la, liver tissue
esctions were fixed in formaldehyde and subjected to heat mediated antigen retrieval
in citrate buffer (pH 6.0). Samples were then blocked for 10 min at room temperature
followed by incubation with a rabbit polyclonal to anti-TNF-a (Abeam, Cambridge,
MA) and a goat IgG anti-IL-la (R&D systems, Minneapolis, MN) antibody at a
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1:200 dilution factor for 30 min. HRP-conjugated goat anti-rabbit (Abeam) and rabbit
anti-goat antibody (Abeam) were used as a secondary antibody.

2.8.4 MPO staining

Myeloperoxidase (MPO) is a peroxidase enzyme which is most abundant in
neutrophils. It is used for indexing neutrophil accumulation in the liver after IRI.
Immunohistochemical staining of MPO was performed by deparaffinating and
rehydrating paraffin sections, and subsequent incubation was performed in a ready-touse peroxidase blocking solution (Dako, Carpinteria, CA) to inhibit endogenous
peroxidase. To block nonspecific background staining, the sections were incubated in
10% horse serum. The sections were then incubated with rabbit IgG anti
myeloperoxidase antibody at a dilution factor of 1:100 (Lab Vision, Fremont, CA),
followed by incubation in EnVision Rabbit-HRP (Dako). After incubating with the
chromogenic substrate, the sections were counterstained with hematoxylin. The slides
were examined under a light microscope (Olympus BX51; Olympus Corp., Tokyo,
Japan) at a magnification of 400x.

2.9 MDA assay
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Lipid peroxidation is a well-established mechanism of cellular injury and is
used as an indicator of oxidative stress in cells and tissues. Lipid peroxides are
unstable and decompose to form a complex series of compounds of which the most
abundant is malondialdehyde (MDA). Therefore, the measurement of MDA is widely
used as an indicator of lipid peroxidation [118].
The MDA-586 assay is based on the reaction between N-methyl-2phenylindole (Rl, NMPI) and MDA at 45°C to form a stable, intensely colored
carbocyanine dye. The reaction is carried out in hydrochloric acid and Probucol to
minimize other lipid peroxidation products from reacting with NMPI to make assay
specific for the MDA detection.
The content of MDA in the homogenate was determined using BIOXYTECH
MDA-586 kit (Oxis Research, Portland, OR), followed by a published protocol [119].
The liver tissues were rapidly excised 6hr after reperfusion and flushed with ice-cold
phosphate-buffered saline (PBS) via the portal vein before homogenization. 200\
300mg of liver tissue was homogenized in 1ml of PBS containing 5mM of butylated
hydroxytoluene. The samples were centrifuged at 14,000g for 10 min and 200pl of
the supernatant was transferred to another eppendorf tube. Probucol and diluted Nmethyl-2-phenylinedole were added to the homogenized liver tissue. After the
addition of hydrochloric acid, the samples were incubated at 45°C for 60 min. The
supernatants were obtained after centrifugation at 14,000 g for 10 min, and the
spectrophotometer was used to detect their absorbance at 586nm (BioRad,
Mississauga, ON).

■i
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2.10 ROS detection- DCF assay
The level of intracellular accumulation of ROS was determined by the T - T dichlorofluorescein (DCF) assay. When 2’, 7’-dichlorofluorescein diacetate (DCFHDA, Sigma) was applied to intact cells and crossed the cell membranes, it was
hydrolyzed by intracellular esterases to nonfluorescent DCFH. In the presence of
ROS, such as oxygen (O2)", hydrogen peroxide (H2O2), hydroxyl radical ( OH), and
singlet oxygen ('0 2 ), DCFH was rapidly oxidized into highly fluorescent T - T dichlorofluorescein (DCF). The increase in the fluorescence can be measured in a
microplate reader at excitation and emission wavelengths of 485 and 525 nm,
respectively. Thus, the DCF fluorescence can be used as an index to quantify the
overall oxidant stress in cells [120-122].
DCFH-DA was dissolved in DMSO to a final concentration of lOpM before
use. Liver tissues were homogenized in a cold Kreb’s buffer (table 2.1). After
centrifugation to remove cell debris, the homogenate (200pg proteins) was incubated
with lOpl of DCF-DA for 30 minutes at 37°C in a 96 well plate. The intensity o f the
fluorescence was recorded using a fluorescence spectrophotometer (Victor 3, Wallac).
ROS levels were calculated as a ratio compared with control liver tissue samples.

Table 2.1 The component of K reb’s buffer
Component

Concentration (mM)

NaCl

118

KC1

4.7

M gS0 4

1.19

NaHC0 3

25

Dextrose

11

KH2PO4

1.0

HEPES

10

CaCl2

1.25

43

2.11 Reverse transcription polymerase chain reaction (RT-PCR)

Total RNA was extracted from liver tissues and B16 cells using Trizol™
(Invitrogen) according the manufacturer’s protocol. In brief, 0.5ml of Trizol Reagent
was added into 6xl05 B16 cells and 50mg of liver tissue (homogenized in the Trizol
Reagent). One hundred microliter of chloroform was added to the mixture and
centrifuged at 15,000rpm at 4°C for 15 min. The top aqueous phase was transferred to
a new tube, and then isopropanol was added and incubated at room temperature for
10 min. After centrifugation, the supernatant was discarded and the ethanol was
added to wash the RNA pellet. After centrifugation, the ethanol was discarded and
the pellet was dried at room temperature. RNase-free water (Invitrogen) was added to
dissolve the RNA and the concentration was measured by a spectrophotometer.
Three microgram of total RNA was reverse-transcribed using an oligo-(dT)
and reverse transcriptase (Invitrogen). The total RNA was mixed with oligo(dT), the
mixture was heated at 70°C for 10 min, and was quickly chilled on ice for 5 min.
RNase inhibitor, dNTP, and reverse transcriptase (NEB) were added, and then the
mixture was incubated at 42°C for 50 min. The reaction was then inactivated at 70°C
for 15 min. The cDNA is now ready for the PCR.
PCR was performed under the following conditions: DNA was initially
denatured at 95°C for 3 min, followed by 30 cycles of denaturation at 95°C for 30 sec,
annealing at 58°C for 30 sec, and then extension at 72°C for 30 sec. A final extension
was performed at 72°C for 10 min. Table 2.2 includes the primer sequence used for
the experiments.
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2.12 Real-time PCR
Real-time PCR reactions were performed in a Stratagene Mx3000P QPCR
System (Agilent Technologies, Lexington, MA) using SYBR green PCR Master Mix
(BioRad) and lOOnM of forward and reverse primers. The sequences were the same
as those used in RT-PCR. The PCR reaction condition was 95°C for 10 min, 95°C for
30 sec, 58°C for 45 sec, and 72°C for 30 sec (40 cycles). Relative quantification
normalized to the GAPDH gene. The 2_AACt method for relative gene expression
analysis is used [123].
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Table 2.2 PCR prim er sequence

Gene

Forward

Reverse

C3

ccctgccccttaccccttcattc

cgtacttgtgcccctccttatctg

TNF-a

ctccctccagaaaagacaccat

atcaccccgaagttcagtagacag

IL -la

cagccttatttcgggagtctattc

tatccctttgttaacccatctgta

ICAM-1

gggcacccagcagaagttgtttt

gctcgacgccgctcagaaga

p-se lectin

aattgctgcctttgcctacgact

tcacctgggctttactgggaacc

GAPDH

ggggtgaggccggtgctgagtat

cattggggtaggaacacggaagg
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2.13 Statistical analysis

The data was expressed as a mean ±SD. Statistical comparisons among groups
were performed using a one-way analysis o f variance followed by the Newman-Keuls
Test. Statistical significance was determined as /?<0.05.

Chapter 3 Results

48

3,1 In vitro delivery of C3 shRNA vector

In order to validate the gene silencing efficacy of the shRNA vectors, I first
determined if shRNA could effectively be transfected into the cells. To do this, I used
an easily- transfected cell line, B16-F10. From 4 to 48hr after transfection, I checked
GFP expression using a fluorescence microscope (Figure 3.1.1) and with flow
cytometry (Figure 3.1.2). The microscope results were able to show that GFP was
already expressed 4hr after transfection, but only in a low intensity. Furthermore,
flow cytometry results revealed that around 30% of cells had a low GFP expression
4hr after transfection (Figure 3.1.2), and that GFP expression was increased time
extented. Forty-eight hours after transfection, 95% of the cells showed fluorescence
of GFP (Figure 3.1.1 & 3.1.2). These results suggest that shRNA can be transfected
into B16-F10 cells and that 48hr after transfection, the cells exhibited the highest GFP
expression with the time frame tested. These results were able to help us concluding
that the 48 hr time frame was the most efficient and desirable time to test for gene
silencing in vitro.

1
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Figure 3.1.1 Time point of GFP expression after transfection

B16-F10 cells were transfected with 1pg of C3 shRNA vector and 2pl of
Lipofectamine 2000™ transfection reagent. From 4 to 48hr after transfection, the
fluorescence of GFP was observed under a fluorescence microscope.
A) non-transfected cells
B) 4hr after transfection
C) 12hr after transfection
D) 24hr after transfection
E) 48hr after transfection
The top panels show green fluorescence. The bottom panels show bright-field phase
image.
Magnification: 100X.

J
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Figure 3.1.2 Flow cytometry analysis of GFP expression after transfection.
B16-F10 cells were transfected with lpg of C3 shRNA vector and 2ul of
Lipofectamine 2000™ transfection reagent. From 4 to 48 hr after transfection, the
cells were harvested and flow cytometry was run to analyze the fluorescence of GFP.
A) non-transfected cells,
B) 4hr after transfection
C) 12hr after transfection
D) 24hr after transfection,
E) 48hr after transfection
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3.2 Silencing of C3 Gene in Vitro

B16-F10 cells were tested using RT-PCR. The results showed that B16 cells have a
very low C3 gene expression. To determine the gene silencing efficacy of C3 shRNA
vectors, we co-transfected C3 cDNA vectors together with C3 shRNA vectors into
B16 cells. Transfection with C3 cDNA resulted in more than a 4-fold upregulation in
the B16 cells. In order to assess the efficacy of gene silencing, cells were co
transfected with C3 cDNA and specific shRNA. Forty-eight hours after co
transfection, the silencing efficacy was determined through RT-PCR (Figure 3.2.A)
and quantitative real time PCR (Figure3.2.B). C3 expression was markedly knocked
down by the C3-1 shRNA vector when compared to the scrambled shRNA
transfected B16 cells. Approximately 90% reduction in C3 gene expression was
achieved in the C3-1 shRNA transfected cells. This data confirmed the success of our
C3 shRNA silencing methodology and provided a reference sequence and dose of
assessment in the in vivo studies.
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Figure 3.2 C3 gene silencing in vitro.
B16-F10 cells were co-transfected with C3 cDNA vectors and C3-1, 2, 3 shRNA or
scrambled shRNA using lipofectamine 2000. Non-transfected cells served as a
negative control. Forty-eight hr after transfection, cells were harvested and total
RNA was extracted. The transcripts of C3 and GAPDH were determined using RTPCR (A) and quantitative real time PCR (B). (* p < 0.05, cDNA +C3-1 shRNA vs.
C3 cDNA + scrambled shRNA).
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3.3 In vivo shRNA delivery and silencing

Previous research demonstrated that systemic administration, using the
“hydrodynamic” injection method, can effectively deliver siRNA into liver tissues
[124]. Therefore, we attempted to deliver C3 shRNA into the liver using the same
method and investigated C3 shRNA in vivo delivery and silencing. Mice were treated
intravenously with l-7mg/kg of C3 shRNA or scrambled shRNA. Forty-eight hours
after treatment, liver tissues were harvested for frozen sections segmenting and the
fluorescence was checked under a microscope (Figure 3.3.1). The results showed that
compared with the lmg/kg shRNA vector treatment, the liver tissue of 5mg/kg
shRNA treatment mice showed a stronger GFP expression. The shRNA vector
treatment was then increased to 7mg/kg. However, there was no significant increase
in GFP expression. This result concluded that a shRNA vector can be successfully
delivered to the liver through hydrodynamic injection.
Next, we tested the gene silencing efficiency in vivo. Hepatocyte is the main
area o f C3 synthesis. To test gene C3 shRNA vector gene silencing, we extracted
RNA from C3 shRNA or scrambled shRNA vector treated mice and performed Real
time PCR (Figure 3.3.2). The results indicated that in contrast with the scrambled
vector, the C3 shRNA vector could dramatically down regulate C3 gene expression in
the liver.
The reduction of C3 gene expression is dose dependent. The dose of lmg/kg
shRNA vector decrease C3 gene expression to around 20-30%. C3 shRNA vector
dose at 2mg/kg can knock down C3 gene expression in vivo by 50%, and at 5mg/kg,
the expression o f C3 was decreased to around 90%. In comparison with the 5mg/kg

57
dose, a 7mg/kg dose did not induce a greater reduction of C3 gene expression in vivo.
Based on these results, the dose of 5mg/kg C3 shRNA was chosen for future studies.
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Figure 3.3.1 In vivo shRNA delivery
Mice were treated with l-7mg/kg C3 or scrambled shRNA vector by hydrodynamic
injection through the tail vein. Forty-eight hours after treatment, liver tissues were
collected and sectioned. The fluorescence of GFP was observed with a microscope.
A) lmg/kg shRNA vector
B) 2mg/kg shRNA vector
C) 5mg/kg shRNA vector
D) 7mg/kg shRNA vector
The top panels show the fluorescence and the corresponding bottom panels exhibit
bright field images.
Magnification: lOOx
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Figure 3.3.2 In vivo gene silencing of C3 gene
Mice were treated with l-7mg/kg C3 or scrambled (control non-targeting) shRNA
vector by hydrodynamic injection through the tail vein. Forty-eight hours after
treatment, liver tissues were collected and RNAs were extracted. Transcripts of C3
and GAPDH were determined using quantitative real time PCR.
(* p < 0.01, 5mg/kg or 7mg/kg C3 shRNA vs. scrambled shRNA, ** p < 0.05,
lmg/kg or 2mg/kg C3 shRNA vs. scrambled shRNA, # jp>0.05, 5mg/kg C3 shRNA
vs.7mg/kg C3 shRNA, ## p<0.5, 5mg/kg C3 shRNA vs. 2mg/kg C3 shRNA. n=6 per
group)
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3.4 Persistence of C3 shRNA silencing in vivo

To further test C3 shRNA vector gene silencing in vivo, we treated mice with
5mg/kg C3 shRNA vector or scrambled shRNA vector by hydrodynamic injection
through tail vein. Liver tissues were collected from day 1 to day 7 after treatment.
RNAs of the liver tissues were extracted and quantitative real time PCR was
performed (Figure 3.4). The results indicated that 24 hr after treatment with the C3
shRNA vector down regulated C3 gene expression in the liver by 50%, scrambled
shRNA could not decrease but rather stimulated C3 gene expression by 10-15% in the
liver. Forty-eight hours after treatment, C3 shRNA decreased C3 gene expression by
80%. Seventy-two hours after treatment the gene silencing efficiency was similar to
that of 48 hr. From day 4 to 7 after shRNA injection, the gene silencing efficiency
decreased to 50%. The results suggested that the efficacy of gene silencing of C3
gene lasted at least 7 days after administration of shRNA, which is sufficient to
protect from IRI most commonly occurring at first 48hr in transplantation. Forty-eight
hours after treating mice with C3 shRNA showed the best effects. Thus, pretreating
with C3 shRNA was injected 48hr before inducing IRI was used for the following
study.

3.5 C3 shRNA prevented C3 gene up-regulation induced by liver IRI

Mice were treated intravenously with 5mg/kg of C3 shRNA or the scrambled
shRNA 48 hr before IRI induction. PBS treated sham-operated (unclamping of
hepatic artery and portal vein to induce IRI) mice served as control. The level of C3
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gene expression in IRI livers was detected by real-time PCR (Figure 3.5). The results
showed that the expression of C3 was significantly increased by IRI. Remarkably, C3
expression induced by IRI in the liver was suppressed in mice pre-treated with C3
shRNA.
3.6 C3 shRNA prevented hepatic dysfunction in IRI

We hypothesized that C3 shRNA could also prevent hepatic damage caused
by complement activation in IR injury. In order to assess the degree of hepatic
dysfunction exhibited by C3 shRNA-treated versus scrambled shRNA-treated mice,
we measured levels o f ALT and AST in sera that were collected from the IRI mice.
Six hours after reperfusion, the levels of AST (Figure 3.6.A) and ALT (Figure 3.6.B)
significantly increased in comparison with those of the unclamped sham controls.
However, in contrast with the scrambled shRNA control, the serum levels o f ALT
(13296.5 ±1178.81U/L vs. 5326.14 ±853.16 U/L p<0.05) and AST (7965.80
±1245.70U/L vs. 2532.40 ± 472.05U/L p<0.05) were significantly reduced in mice
pre-treated with C3 shRNA. Twenty-four hours after reperfusion, the serum level of
ALT and AST in C3 shRNA-treated mice remained at low levels, which were
significantly low in comparison with those of the scrambled shRNA-treated mice.
These results suggest that C3 shRNA protected liver from IRI.
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Figure 3.4 Persistence of C3 shRNA silencing in vivo
Mice were treated with the 5mg/kg C3 shRNA vector or the scrambled shRNA vector
by hydrodynamic injection through the tail vein. From day 1 to day 7 after treatment,
liver tissues were collected and RNAs from these liver tissues was extracted.
Transcripts of C3 and GAPDH were determined using quantitative Real time PCR
analysis. (*p<0.05, C3 shRNA vs. scrambled shRNA from day 1 to day 7, n=6 per
group)
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Figure 3.5 C3 shRNA decreased C3 gene up-regulation induced by liver ERI
C3 shRNA or scrambled shRNA at the dose of 5mg/kg diluted in a volume of 2 ml
were administered to mice through i.v. injections as described in Material and
Methods. Forty-eight hours after injection, liver hepatic arteries and portal veins
were clamped for 60 min to induce IRI. PBS treated sham-operated (unclamping of
hepatic artery and portal vein to induce IRI) mice served as sham controls. Six hours
after reperfusion, liver tissues were harvested and total RNAs were extracted.
Transcripts of C3 and GAPDH were determined by quantitative real time PCR. (* p <
0.01, C3 shRNA treated group vs. scrambled shRNA treated group, n=6 per group).
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Figure 3.6 C3 shRNA reduced the effect of liver ischemia and reperfusion on
liver function.
Serum samples were extracted after 60 min of ischemia and 6 or 24hr of reperftision.
Sera was collected from sham control mice and mice with IRI treated with C3 shRNA
or scrambled shRNA. Serum levels of ALT (A) and AST (B) were detected as
described in Methods and Materials. The data shown is the mean ± SD (* p < 0.05;
C3 shRNA treated group vs. scrambled shRNA treated group, n=6 per group).
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3.7 Histological changes in IRI after silencing C3 genes

To confirm the effects of shRNA, we further examined histopathological
changes in the IRI livers. We collected liver tissues 6 hr and 24 hr after reperfusion.
The histological score was based on the degree of congestion, vacuolization, and the
area of hepatic necrosis (Table 3.1). Six hours after reperfusion, the livers from mice
treated with scrambled shRNA were induced with profound IRI. Severe tissue
damage was observed in the IRI liver, such as congestion, vacuolization, and necrosis
(Figure 3.7). In contrast, mice pre-treated with C3 shRNA showed a significant
attenuation of all pathological changes examined by 67-75% (Table 3.1).

3.8 C3 shRNA decreased the neutrophils infiltration in the IRI liver

Neutrophil accumulation is an important factor in liver IRI [117, 125]. MPO is
a peroxidase enzyme most abundantly present in neutrophil granules.. To assess
complement activation in hepatic IR injury on neutrophil accumulation, liver tissue
samples were stained with an antibody against MPO. There was no appreciable
neutrophil infiltration in the liver tissues of the sham-operated mice. However, in the
scrambled shRNA treated group, a considerable number of neutrophils were
identified in the livers at both 6 and 24hr after reperfusion. There was a higher
neutrophil infiltration at 24hr than at 6hr after IRI in the scrambled shRNA treated
mice. The livers of mice treated with C3 shRNA had a significantly decreased
neutrophil accumulation at 6 and 24 hr after reperfusion. (Figure 3.8)
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Table 3.1

Histopathological score of IRI

Groups

Congestion

Vacuolization

Necrosis

Sham

0.14±0.09

0.07±0.07

0.00±0.00

Scrambled shRNA

2.57±0.17

2.29±0.15

2.67±0.17

C3 shRNA

0.86±0.14 *

0.57±0.20 *

0.70±0.12 *

Liver IRI was induced by clamping the hepatic artery and portal vein for 60 min. Six
hours after IRI, liver tissues were harvested and stained with H&E. The
histopathological change was scored as indicated in Materials and Methods. The
data shown is the mean± SEM. (*p<0.05 C3 shRNA group vs. scrambled shRNA
group, n=6 per group).
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Figure3.7 Hepatic histopathology
BALB/c mice were pretreated with PBS (A) scrambled shRNA (B) or C3 shRNA
(C). IRI was induced as described in Figure 3.5. Liver tissues were harvested 6hr
after reperfusion and stained with H&E.
Magnification: 200x
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Figure3.8 Liver tissues stained with MPO
BALB/c mice were pretreated with C3 shRNA, scrambled shRNA, or PBS and were
induced with IRI as described in Figure 3.7. At 6hr and 24hr after reperfusion, liver
tissues were harvested. Paraffin-embedded sections were stained with a monoclonal
antibody against MPO.
Magnification: 200x
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3.9 C3 shRNA reduced hepatic IRI induced pro-inflammatory cytokine release

Proinflammatory cytokines such as TNF-a and IL -la [56, 60, 66] are
generated mainly by Kupffer cells. Complement activation in IRI can stimulate
Kupffer cells to release TNF-a and IL-la, aggravating hepatic injury. Through real
time PCR (Figure 3.9.1) and immunohistochemistry (Figure 3.9.2), mice treated with
C3 shRNA were shown to exhibit notably reduced levels of TNF-a and IL -la in liver
tissues in comparison with scrambled shRNA treated mice observed 6hr after
reperfiision injury.

3.10 C3 shRNA reduced IRI induced adhesion molecules expression

When Kupffer cells are activated, they release proinflammatory cytokines.
TNF-a is responsible for increasing the adhesion molecule P-selectin, ICAM-1, and
chemokine expression which further promote neutrophil accumulation in the liver
[126]. We proved that treating mice with C3 shRNA can significantly decrease TNFa and IL -la level in liver tissues (Figure 3.9.1 and 3.9.2). Therefore, we tested
adhesion molecule P-seletin and ICAM-1 expression in liver tissues 6 hr after the
reperfusion injury (Figure 3.10). The quantitative real time PCR results showed that
treating mice with C3 shRNA significantly decreased the expression of ICAM-1 and
P-selectin.
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Figure 3.9.1 TNF-a and IL -la levels detected by real-time PCR
BALB/c mice were pretreated with C3 shRNA, scrambled shRNA, or PBS and were
induced with IRI as described in Figure 3.5. A & B: TNF-a and IL -la level in liver
tissue detected by real-time PCR. Transcripts of TNF-a (A) and IL -la (B) were
determined by quantitative real time PCR. The data shown is the mean ± SEM (*p <
0.05, C3 shRNA treated group vs. scrambled shRNA treated group, n=6 per group)
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Figure 3.9.2 Immunohistochemistry staining for TNF-a and IL -la
BALB/c mice were pretreated with C3 shRNA, scrambled shRNA, or PBS and were
induced with IRI as described in Figure 3.5. TNF-a and IL-la level in liver tissues
were detected by immunohistochemistry. Paraffin sections were stained with an
antibody against TNF-a and IL-la, as described in Materials and Methods.
Magnification: 200x
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Figure 3.10 C3 shRNA reduced IRI induced adhesion molecules expression
BALB/c mice were pretreated with C3 shRNA, scrambled shRNA, or PBS and were
induced with IRI as described in Figure 3.5. A & B: ICAM-1 and P-selectin levels in
liver tissues were detected by real-time PCR. Transcripts of ICAM-1 (A) and Pselectin (B) were determined by quantitative real time PCR. The data shown is the
mean± SEM (*p < 0.05, C3 shRNA treated group vs. scrambled shRNA treated group,
n=6 per group)
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3.11 C3 shRNA decreased malondialdehyde level in IRI liver tissue.

Lipid peroxidation is a well-established mechanism of cellular injury that is
used to indicate oxidative stress in cells and tissues [127]. The measuring of
malondialdehyde (MDA) levels is widely used as an indicator of lipid peroxidation in
testing levels o f oxidative damage. The initial phase of hepatic IR injury involves
Kupffer cell activation and induced oxidative stress. Complement activation can
activate Kupffer cells in hepatic ischemia reperfusion injury. In this study, we
pretreated mice with C3 shRNA prior to inducing IR injury and found that compared
with scrambled shRNA treated mice, C3 shRNA treated mice exhibited a significant
depression of MDA levels. (Figure 3.11)

3.12 C3 shRNA reduced ROS in IRI liver tissue

Kupffer cell activation can release ROS after liver IRI. Complement
activation can further activate Kupffer cells to generate more ROS. To test the
oxidative stress injury in liver tissues, we also examined the ROS production in liver
tissues using DCF assay [122] (Figure 3.12). The ROS production was significantly
decreased in the mice treated with C3 shRNA in comparison with those treated with
the scrambled shRNA vector group. This result along with those obtained from the
MDA experiment, suggest that C3 shRNA treatment can significantly decrease the
oxidative injury after reperfusion injury in liver tissues.
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Figure 3.11 C3 shRNA decreased oxidative injury in IRI liver.
BALB/c mice were pretreated with C3 shRNA, scrambled shRNA, or PBS and were
induced with IRI as described in Figure 3.5. Six hours after reperfusion, liver tissues
were harvested and the MDA content was determined using a MDA 586 kit, as
described in Materials and Methods. The data shown is the mean ± SEM (*.P<0.05
C3 shRNA treated group vs. scrambled shRNA treated group, n=6 per group)
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Figure 3.12 ROS production in liver tissue
BALB/c mice were pretreated with C3 shRNA, scrambled shRNA, or PBS and were
induced with IRI as described in Figure 3.5. Six hours after reperfusion, liver tissues
were harvested. The ROS production of liver tissues was measured a DCF assay as
described in M aterial and Methods. The data shown is the mean ± SEM (*P<0.05
C3 shRNA treated group vs. scrambled shRNA treated group, n=6 per group)
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C hapter 4 Discussions

Liver IRI during transplantation or liver surgery is still a major concern that
can ultimately lead to organ dysfunction and/or failure. There are two distinct phases
of liver IRI: the initial phase, which occurs in less than 2 hr of reperfusion, and the
late phase, which occurs at 6-48h after reperfusion[14], The initial phase involves
Kupffer cell activation, ROS production, and oxidative stress, which all eventually
lead to the damaging of hepatocytes. In the late phase, which is associated with
neutrophil infiltration, [39, 117, 128], the recruited neutrophils directly damage the
hepatocytes by releasing oxidants and proteases [22].
The pathogenic mechanisms involved in IRI are complex and multifaceted but
clinical and experimental studies in several organ systems, including that of the liver,
have revealed that complement activation plays a major role in IRI [129-133].
Ischemia and reperfusion is a potent inducer of complement activation. Activated
complement and inflammatory cells are involved individually and collaboratively in
the formation of IRI. Complement is a complex cascade of 30 soluble and membrane
bound proteins that are activated in an orderly manner by 3 different pathways. These
three pathways are known as the classical, alternative, and MBL pathways. All 3
pathways merge at the level of the complement component C3 and culminate in a
common terminal pathway to generate chemotactic factors such as C3a and C5a and a
terminating complex called the MAC (C5b-9). It seems that the specific contribution
of the three pathways vary depending on the pathophysiologic mechanism in IRI of
different organs. Several studies demonstrated that the classical or lectin pathway is
involved in myocardial, gastrointestinal and, hind limb IRI [134-138]. The alternative
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pathway may contribute to kidney IRI [139] and the classical pathway is involved in
liver IRI [140],
In humans, complement activation leading to the deposition of MAC is
common during liver transplantation and contributes to cell injury and neutrophils
infiltration to the allograft [141]. The MAC incorporated into the cellular membrane
can activate endothelial NF-kB and increase the number adhesion molecules such as
ICAM-1, VCAM-1 and P-selectins expression [142, 143]. The MAC can also
stimulate endothelium to produce IL-8 and monocyte chemo attractant protein-1
[144]. Furthermore, it can activate platelets and contribute to platelet-leukocyte
aggregation [145].
C3a and C5a, generated from complement activation, participate in neutrophil
accumulation. C5a can cause the increase of P-selectin and ICAM-1 expression,
which mediate neutrophils and endothelial cells to form a firm adhesion. C5a, as a
more potent inflammatory mediator, can also release pro inflammatory cytokines such
as TNF-a and IL-la. As a strong chemo attractant, C5a can also recruit neutrophils to
the injury site. The accumulation of neutrophils augments the injury of reperiusion.
Since complement activation plays a key role in inducing IRI, it can be hypothesized
that IRI can be attenuated through the use of complement inhibitors.
The contribution of complement in IRI has been well demonstrated in
complement deficient models. Attenuated injuries were observed in the intestinal and
hind limb IRI models of C3‘/_ and C4'/_ mice [134, 146, 147]. Another study showed
that the mice in which C3 was deficient exhibited a protective effect in a renal IRI
model [148]. In terms of therapeutics in preventing liver IR injury, block complement
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pathways using a C3 convertase inhibitor [33, 149], C5aR antagonist [150], and Cl
inhibitor [98, 140, 151] have been effective in ameliorating liver IRI in rodent models.
C3 was selected as a target for gene silencing in this study because it is the critical
plasma protein of the complement pathway. It was predicted that its inhibition would
effectively terminate the activation of the downstream complement cascade.
RNAi is a natural mechanism by which siRNA mediates the sequence specific
cleavage of targeted RNA molecules. Therefore, RNAi is a powerful tool for the
target specific knockdown of gene expression. Ever since this method of using RNAi
was named the “ breakthrough of the year” in 2002 [152], there have been numerous
studies using this novel technology which have provided results that could eventually
be used for therapeutic applications. The therapeutic advantages of siRNA for
treatment of viral infections, cancer, and neurological disorders show a great promise
[153-155]. In comparison with antibodies, the prospects for siRNA are better because
it is easily applicable to any therapeutic target including intracellular factors and even
transcription factors. Also, gene silencing with siRNA is more powerful and exhibits
exquisite selectivity. Amongst its other advantages, siRNA also has a low toxicity and
provides easy screening for inhibition efficiency.
For siRNA delivery in vivo, previous studies have demonstrated that the liver
is the primary site of siRNA uptake after hydrodynamic injection [113]. Song et al
used Fas siRNA, which holds a therapeutic promise to prevent liver injury by
protecting hepatocytes from cytotoxicity [106]. Another study showed that by treating
mice with caspase 8 siRNA through hydrodynamic injection can prevent acute liver
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failure [156]. Therefore, delivering siRNA to the liver by means of hydrodynamic
injection is a proven and promising strategy for liver disease.
Naked non-chemical modification siRNA is relatively unstable in the blood
and is rapidly cleared from the body via degradation by ribonucleases, rapid renal
excretion, and nonspecific uptake by the reticuloendothelial system. Compared with
siRNA, the shRNA vector is more stable and has a longer duration of silencing
efficiency. RNAi using shRNA is a potent strategy in knocking down genes in vivo
[101]. We have previously demonstrated that the treatment of shRNA that are specific
to complement genes had a promising therapeutic potential in preventing heart [108]
and renal IR1 [109-112]. In this study, we were able to prove that gene silencing of
C3 using shRNA is effective in ameliorating liver IRI (Figure 3.6).
The liver (mainly hepatocytes) is responsible for the biosynthesis of 90% of
injection is an efficient method for delivering shRNA plasmids to hepatocytes [113115, 124], In this study, we demonstrated that successfully delivering and silencing
C3 using a shRNA plasmid in the liver resulted in the prevention of liver IRI (figure
3.5, 3.6).
The early phase of liver IR injury activates Kupffer cells which produce
harmful levels of ROS. The release of ROS directly damages liver tissues in IR
injury, moreover, ROS also stimulates Kupffer cells to produce pro-inflammatory
cytokines such as TNF-a and IL -la [158]. TNF-a is produced by many cell types,
including Kupffer cells, in response to various inflammatory and immunomodulatory
stimuli in liver IRI. In this study, we detected elevated levels o f TNF-a in the liver IRI
mice, similarly shown in rat liver IRI models, in which TNF-a increased almost five

folds compared with sham operated controls [159].

The proposed mechanisms by

which TNF-a leads to liver IRI mainly do not include the mediation of direct toxicity
to the mitochondria or inducing apoptotic or necrotic cell death.[l 59-161]. The
increasing of IL -la was also observed in this study, showing that it may be stimulated
by the inflammatory environment of liver IR or from its response to the upregulation
of TNF-a. Interestingly, a feedback loop between ROS and inflammatory cytokines
may exist. While ROS stimulates TNF-a/IL-la to be released, TNF-a/IL-la also
promotes neutrophils to produce ROS. In the late phase, IL-la may activate the
infiltrated neutrophils in liver IRI, which will result in the production ROS [128],
Turning off this feedback loop is seemingly impossible unless all pathways involved
are efficiently blocked. In this study, the knockdown of the C3 pathway significantly
attenuated the production of both ROS and inflammatory cytokines. Our results
showed that by silencing C3 gene expression in IRI, the liver will down-regulate its
levels TNF-a, IL -la and decrease the generation of ROS (Figure 3.9.1, 3.9.2, 3.12).
Neutrophils are involved in both phases of hepatic IRI. Kupffer cell activation
and the release of pro-inflammatory cytokines, such as TNF-a and IL-la, can activate
the systemic neutrophil function and lead to the accumulation and adherence of
neutrophils to hepatocytes, inducing hepatocyte necrosis. With complement factors
and platelet activating factor, TNF-a and IL-la can induce neutrophil accumulation in
the liver. Furthermore, TNF-a and complement factors can upregulate CXC
chemokines and adhesion molecule expression to augment neutrophil accumulation
and induce neutrophil-mediated injury after reperfusion. Blocking the complement
pathway using C3 shRNA can significantly decrease pro-inflammatory cytokine

levels and adhesion molecules P-selectin and ICAM-1 expression, promoting a
decrease of neutrophil infiltration in liver tissues.
Lipid peroxidation refers to the oxidative degradation of lipids and is used as
an indicator of oxidative stress in cells and tissues. Lipid peroxides are unstable and
decompose to form a complex series of compounds, of which the most abundant is
MDA. Our results indicated that by knocking down C3 gene expression in the liver,
IRI can be alleviated hepatic MDA levels (Figure 3.11).
In conclusion, our studies have demonstrated that the systemic administration
of C3 shRNA resulted in the silencing of C3 expression, prevented IRI, suppressed
inflammatory cytokine production, and withheld neutrophil infiltration in the liver.
The use of C3 shRNA may eventually represent a novel approach in preventing
complement mediated liver damage and become an efficient aid in liver
transplantations and other conditions associated with liver IRI.

Future study
Effective in vivo delivery of siRNAs to specific target organs or cells is the
most important challenge in respect of clinical applications. In this study, we
demonstrated that treating mice with a C3 shRNA vector by means of hydrodynamic
injection through the tail vein successfully delivered shRNA to the liver, knocked
down C3 gene expression, and prevented liver IRI in a murine model. But this high
volume, high pressure intravenous injection of siRNA or shRNA is not practical in
clinical interventions. The ability to selectively deliver siRNA to specific cells would
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allow for lower concentrations of siRNA to be used, as well as possibly alleviating
the need for systemic delivery.
Cationic liposomes or nanoparticles have been used for siRNA in vivo
delivery. Among these approaches, the most efficient systemic administration was
achieved using stable nucleic acid lipid particles. Receptor-mediated liposomes may
be able to provide an efficient method for siRNA systemic delivery.
Asialoglycoprotein is expressed on the surface of the hepatocyte. Galactose
specifically binds to the asialoglcorprotein receptor. In order to achieve hepatocytetargeted delivery of siRNA, conjugating galactose to the liposome is hypothesized to
provide a novel method of specifically delivering siRNA to the liver. The lipid-based
liposome in combination with specific ligands for cell-target delivery of siRNA may
also provide a way for the successful systemic delivery of siRNA based therapeutics.
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Dear Dr. M in :
Y ou r Anim al U se Protocol form entitled:
Novel S trategy fo r Inducing T ra n s p la n t Tolerance by Perfusion w ith s iR N A
Funding A g en cy M U L T IO R G A N T R A N S P L A N T P R O G R A M - Grant #LH R F7594
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1. This num ber must be indicated when ordering animals for this project.
2. Anim als for other projects m ay not be ordered under this number.
3. If no num ber appears please contact this office when grant approval is received.
(f the application for funding is not successful and you wish to proceed with the project, request that an interna)
scientific peer review be performed by the Animal U se Subcommittee office.
4. Purchases of animals other than through this system must be cleared through the A C V S office. Health
certificates will be required.
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O th e r Detail

Pain
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4-6 weeks male

D
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D
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C57BL6

6-8 week male

D

1440
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6-8 week mate

D
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230-2SDgm male

D

840
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Sprague Dawley
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Lewis

230-250 gra male

D

1040

Dark Agouti

230-250 g m m a le

D

1040

Rat

R E Q U IR E M E N T S / C O M M E N T S
Please ensure that individuals) performing procedures on live animals, as described in this protocol, are familiar
with the contents of this document.

e .c. Approved Protocol
Approval Letter

- W . Min, X . Zhang, W . Lagerwert
- W . Min, X. Zhang. W . Lagerwerf

The University o/W estern Ontario
Animal Use Subcommittee / University Council on Animal Care
Health Sciences Centre, • London, Ontario • CANADA - N6A 5C1
PH: 5 19-661-2 I I I ext. 66770 • FL 519-661-2028 • www.mvo.ca/ammal
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